Joseph E. Grossman

Jun 13, 2024 | nature.com | Andrea Bullock |Benjamin L. Schlechter |Marwan Fakih |Joseph E. Grossman |Rachel E. Sanborn |Bruno Bockorny | +3 more

AbstractMicrosatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.